DelveInsight’s, "Metastatic Pancreatic Cancer Pipeline Insight, 2023,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Metastatic Pancreatic Cancer pipeline landscape. It covers the pipeline drug profiles, including Metastatic Pancreatic Cancer clinical trials and nonclinical stage products. It also covers the Metastatic Pancreatic Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Metastatic Pancreatic Cancer Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Metastatic Pancreatic Cancer NDA approvals (if any), and product development activities comprising the technology, Metastatic Pancreatic Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Metastatic Pancreatic Cancer Pipeline Report
- DelveInsight’s Metastatic Pancreatic Cancer pipeline report depicts a robust space with 25+ active players working to develop 25+ pipeline therapies for Metastatic Pancreatic Cancer treatment.
- The leading Metastatic Pancreatic Cancer Companies includes Jiangsu HengRui Medicine, Eleison Pharmaceuticals, Panbela Therapeutics, SynerGene Therapeutics, Salspera, BioLineRx, Ocuphire Pharma, Incyte Corporation, Eli Lilly and Company, Rexahn Pharmaceuticals, AB Science, Takeda Oncology, and others.
- Promising Metastatic Pancreatic Cancer Pipeline Therapies includes ACP-196, Galunisertib, Durvalumab, Gemcitabine, Albumin-bound paclitaxel, RX-3117, Olaratumab, Nab-paclitaxel, MM-398, Leucovorin, and others.
- The Metastatic Pancreatic Cancer Companies and academics are working to assess challenges and seek opportunities that could influence R&D Metastatic Pancreatic Cancer. The Metastatic Pancreatic Cancer pipeline therapies under development are focused on novel approaches to treat/improve Metastatic Pancreatic Cancer.
To explore more information on the latest breakthroughs in the Metastatic Pancreatic Cancer Pipeline treatment landscape of the report, click here @ Metastatic Pancreatic Cancer Pipeline Outlook
Metastatic Pancreatic Cancer Overview
Pancreatic cancer refers to the carcinoma arising from the pancreatic duct cells, pancreatic ductal carcinoma. It is the fourth leading cause of cancer deaths in the United States. The 5-year survival rate in the United States ranges from 5% to 15%. The overall survival rate is only 6%. Surgical resection is the only current option for a cure, but only 20% of pancreatic cancer is surgically resectable at the time of diagnosis. In metastatic pancreatic cancer, surgery is used only for symptom control, such as for pain, jaundice, or gastric outlet obstruction. Radiation may be used for symptom relief, as well. Metastatic Pancreatic cancer has clearly spread to other organs, so surgery cannot remove the cancer.
Metastatic Pancreatic Cancer Emerging Drugs Profile
Motixafortide: BioLineRx
Motixafortide (formerly known as BL-8040/BKT140) is a novel selective inhibitor of the CXCR4 chemokine receptor. CXCR4, is a well validated therapeutic target that is involved in the mobilization and trafficking of hematopoietic stem cells, immune cells and cancer cells from the bone marrow and the lymph nodes to the peripheral blood. Motixafortide is being developed as a platform for several indications including mobilization of hematopoietic stem cells (HSCs) for autologous transplantations, treatment of solid tumors, and other hematological malignancies.
Fuzuloparib: Jiangsu Hengrui Pharmaceuticals
Fuzuloparib is a small molecule, orally active PARP inhibitor being developed by Jiangsu Hengrui Pharmaceuticals Co for the treatment of solid cancers. Fuzuloparib has been approved in China for the treatment of ovarian cancer (including fallopian tube cancer or primary peritoneal cancer), and phase II and III trials are investigating fuzuloparib for the treatment of other solid cancers, including cancers of the pancreas, breast, prostate and lungs.
HP518: Hinova Pharmaceuticals
HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR) with the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations. In discovery and preclinical studies, HP518 showed high degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide, and excellent antitumor activity in xenograft mouse models. HP518 is highly selective for AR.
For further information, refer to the detailed Metastatic Pancreatic Cancer Unmet Needs, Metastatic Pancreatic Cancer Market Drivers, and Market Barriers, click here for Metastatic Pancreatic Cancer Ongoing Clinical Trial Analysis
Metastatic Pancreatic Cancer Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the therapies Metastatic Pancreatic Cancer. The companies which have their Metastatic Pancreatic Cancer drug candidates in the most advanced stage, i.e phase III include Eleison Pharmaceuticals
Metastatic Pancreatic Cancer Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Request a sample and discover the recent advances in Metastatic Pancreatic Cancer Ongoing Clinical Trial Analysis and Medications, click here @ Metastatic Pancreatic Cancer Treatment Landscape
Scope of the Metastatic Pancreatic Cancer Pipeline Insight Report
- Coverage- Global
- Metastatic Pancreatic Cancer Companies- Jiangsu HengRui Medicine, Eleison Pharmaceuticals, Panbela Therapeutics, SynerGene Therapeutics, Salspera, BioLineRx, Ocuphire Pharma, Incyte Corporation, Eli Lilly and Company, Rexahn Pharmaceuticals, AB Science, Takeda Oncology, and others.
- Metastatic Pancreatic Cancer Pipeline Therapies- ACP-196, Galunisertib, Durvalumab, Gemcitabine, Albumin-bound paclitaxel, RX-3117, Olaratumab, Nab-paclitaxel, MM-398, Leucovorin, and others
- Metastatic Pancreatic Cancer Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for drugs for Metastatic Pancreatic Cancer Market Drivers and Metastatic Pancreatic Cancer Market Barriers, click here @ Metastatic Pancreatic Cancer Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Metastatic Pancreatic Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Metastatic Pancreatic Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Rucaparib: Eleison Pharmaceuticals
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- MDB 401 B: Panbela Therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- SBP 101: Takeda Oncology
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Metastatic Pancreatic Cancer Key Companies
- Metastatic Pancreatic Cancer Key Products
- Metastatic Pancreatic Cancer- Unmet Needs
- Metastatic Pancreatic Cancer- Market Drivers and Barriers
- Metastatic Pancreatic Cancer- Future Perspectives and Conclusion
- Metastatic Pancreatic Cancer Analyst Views
- Metastatic Pancreatic Cancer Key Companies
- Appendix
Got Queries? Find out the related information on Metastatic Pancreatic Cancer Mergers and acquisitions, Metastatic Pancreatic Cancer licensing activities @ Metastatic Pancreatic Cancer Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
